|
Originally published In Press as doi:10.1074/jbc.M112281200 on February 27, 2002
J. Biol. Chem., Vol. 277, Issue 23, 21027-21040, June 7, 2002
Quality Control in the Yeast Secretory
Pathway
A MISFOLDED PMA1 H+-ATPase REVEALS TWO
CHECKPOINTS*
Thierry
Ferreira ,
A. Brett
Mason§,
Marc
Pypaert¶,
Kenneth
E.
Allen, and
Carolyn W.
Slayman
From the Department of Genetics and the ¶ Center for Cell and
Molecular Imaging, Yale University School of Medicine,
New Haven, Connecticut 06510
Received for publication, December 21, 2001, and in revised form, February 25, 2002
 |
ABSTRACT |
The yeast plasma-membrane
H+-ATPase, encoded by PMA1, is delivered
to the cell surface via the secretory pathway and has recently emerged
as an excellent system for identifying quality control mechanisms along
the pathway. In the present study, we have tracked the biogenesis of
Pma1-G381A, a misfolded mutant form of the H+-ATPase.
Although this mutant ATPase is arrested transiently in the peripheral
endoplasmic reticulum, it does not become a substrate for endoplasmic
reticulum-associated degradation nor does it appear to stimulate an
unfolded protein response. Instead, Pma1-G381A accumulates in
Kar2p-containing vesicular-tubular clusters that resemble those
previously described in mammalian cells. Like their mammalian
counterparts, the yeast vesicular-tubular clusters may correspond to
specific exit ports from the endoplasmic reticulum, since Pma1-G381A
eventually escapes from them (still in a misfolded, trypsin-sensitive
form) to reach the plasma membrane. By comparison with wild-type
ATPase, Pma1-G381A spends a short half-life at the plasma membrane
before being removed and sent to the vacuole for degradation in a
process that requires both End4p and Pep4p. Finally, in a separate set
of experiments, Pma1-G381A was found to impose its phenotype on
co-expressed wild-type ATPase, transiently retarding the wild-type
protein in the ER and later stimulating its degradation in the vacuole.
Both effects serve to lower the steady-state amount of wild-type ATPase
in the plasma membrane and, thus, can explain the co-dominant genetic
behavior of the G381A mutation. Taken together, the results of this
study establish Pma1-G381A as a useful new probe for the yeast
secretory system.
 |
INTRODUCTION |
In eukaryotic cells, plasma membrane proteins are delivered to the
cell surface by the secretory pathway, whose port of entry is the
endoplasmic reticulum (ER).1
Not surprisingly, quality control mechanisms have evolved to detect and
eliminate misfolded proteins at several points along the pathway. Many
proteins that fail to fold properly in the ER are eliminated by a
process known as ERAD (ER-associated degradation), which transports
them back into the cytoplasm to be degraded in a
ubiquitin-dependent manner by the proteasome (1-3). In the event of excessive ER stress, the ER-associated degradation pathway is
complemented by the unfolded protein response, a stress response that
involves transcriptional induction of a set of target genes encoding ER
chaperones and other products involved in ER function (4-6). Misfolded
proteins that escape the ER may encounter a second, Golgi-based quality
control mechanism, recently detected in yeast, which sends them to the
vacuole for degradation (7-10). Finally, recognition mechanisms exist
at the plasma membrane to down-regulate many transporters and receptors
by endocytosis in response to specific physiological signals (reviewed
by Hicke (11, 12)); at least in principle, these or related mechanisms could function to remove misfolded proteins that manage to reach the
cell surface (e.g. Ref. 13).
The present study has focused on the yeast plasma-membrane
H+-ATPase as a model to investigate quality control during
biogenesis. The H+-ATPase belongs to a large, widely
distributed family of transporters known as the P-type cation pumps
(14); it is encoded by the PMA1 gene (15) and is the most
abundant protein in the yeast plasma membrane. Work in many
laboratories has established that the physiological function of the
H+-ATPase is to pump protons out of the cell, setting up
the driving force for nutrient uptake by
H+-dependent cotransporters (reviewed by Rao
et al. (16)). Consistent with predictions from hydropathy
analysis (15), there is now good evidence from cryo-electron microscopy
that the 100-kDa H+-ATPase is embedded in the lipid bilayer
by 10 membrane-spanning -helices, four at the N-terminal end of the
molecule and six at the C-terminal end (17). Its central portion
protrudes into the cytoplasm and contains ligand-binding sites needed
for catalysis. These structural characteristics are supported by
comparison with the 2.6-Å crystal structure of the P-type
Ca2+-ATPase from rabbit sarcoplasmic reticulum (18).
The yeast H+-ATPase is known to be delivered to the cell
surface via the secretory pathway, since it can be trapped in the ER,
Golgi, or secretory vesicles by temperature-sensitive mutations of
SEC18, SEC7, or SEC6 (19-22). More
than 300 point mutations have been introduced into the PMA1
gene by site-directed mutagenesis; others have been selected by
resistance to hygromycin B (reviewed by Morsomme et al.
(23)). Taken together, these mutants provide a wealth of material for
exploring the relationship between H+-ATPase structure and
the components of various quality control mechanisms.
A particularly striking example comes from recent work on mutations of
Asp-378, a key residue that is conserved in all P-type ATPases and
forms a transient -aspartyl phospho-intermediate during ATP
hydrolysis. Unexpectedly, Pma1 H+-ATPases carrying point
mutations of Asp-378 are retained in the ER and, when co-expressed with
the wild-type ATPase, display a dominant lethal phenotype (16, 24-27).
The ER arrest of Asp-378 mutants has been traced to gross misfolding,
as evidenced by the extreme sensitivity of Pma1-D378N, Pma1-D378S, and
Pma1-D378A to low concentrations of trypsin (25, 27). More recently, Wang and Chang (28) have shown that Pma1-D378N is ultimately ubiquitinated and degraded, presumably by the proteasome. To identify components of the ER quality control machinery, they exploited the
dominant lethal phenotype of the D378N mutant to select suppressors from a mutagenized genomic library carrying random insertions of
lacZ and LEU2. Indeed, one such suppressor
(eps1 ) allowed Pma1-D378N to move from the ER to the
plasma membrane; the corresponding gene (EPS1) proved to
encode a novel member of the protein disulfide isomerase-related
family, which may function as a quality control chaperone to retain
Pma1-D378N in the ER.
Chang and co-workers (7, 9, 10) have also used a
temperature-sensitive mutant of the yeast H+-ATPase,
pma1-7, to probe the organization of the secretory pathway. At the restrictive temperature, this mutant protein exits the ER but is
then shunted from the Golgi to the vacuole for degradation (7).
Screening with a high copy genomic library has yielded two suppressors
(AST1 and AST2) whose products, when
over-expressed, can re-route Pma1-7 to the plasma membrane (7). In
parallel, 16 different insertional suppressors of pma1-7
have been isolated (9) and are being used to define the components of
two distinct pathways by which Pma1-7 is diverted to the cell surface
(10). Although there is not yet any direct information on the structure of the Pma1-7 mutant protein, it must be capable of folding relatively well even at 37 °C, since in the presence of an appropriate
suppressor mutation, it reaches the plasma membrane, hydrolyzes ATP at
a measurable rate, and supports growth (7, 9, 10).
The goal of the present study was to see whether new information about
the yeast secretory pathway could be obtained with the help of a
different mutant form of the H+-ATPase, Pma1-G381A, which
is moderately sensitive to trypsin and, thus, appears to be
intermediate in structure between Pma1-D378N and Pma1-7 (25). Although
immunofluorescence studies have shown that Pma1-G381A can reach the
plasma membrane, it lacks detectable enzymatic activity and displays a
co-dominant phenotype when co-expressed with the wild-type
H+-ATPase, suggesting that it may interact in an
informative way with one or more components of the quality control
machinery. We have carefully tracked the expression of epitope-tagged
Pma1-G381A as a function of time. Initially, the mutant protein induces
dramatic proliferation of a morphologically well defined compartment
derived from the peripheral ER, in which it transiently accumulates
along with the ER-resident chaperone Kar2p (BiP). Pma1-G381A then
escapes this compartment and reaches the secretory vesicles, still in a
misfolded form. As a consequence, it is relatively unstable at the
plasma membrane, being removed rapidly by endocytosis for degradation
in the vacuole. Significantly, the mutant form is able to impose its
phenotype on co-expressed wild-type ATPase, which likewise becomes
retarded in the ER and then quickly degraded upon arrival at the plasma membrane.
 |
EXPERIMENTAL PROCEDURES |
Strains, Plasmids, and Growth Conditions--
The
Saccharomyces cerevisiae strains and plasmids used in this
study are listed in Table I.
Standard yeast media and genetic manipulations were as described by
Sherman et al. (35), and yeast transformations were
performed by the lithium acetate method (36). Strains TFY25 and TFY54
were derived from a cross between NY605 and NY1174; strain TFY1 was
derived from a cross between TFY25 and RH268-1; and strains TFY15 and
TFY32 were derived from a cross between TFY54 and SY2. For expression
studies, derivatives of strains TFY1, TFY15, TFY32, WG4a, and
W303 were constructed in which the chromosomal copy of the
PMA1 gene was placed under control of the GAL1
promoter (37) by transforming yeast with the integrative plasmid
YIpGAL-PMA1 (32) linearized with BstEII; URA3 served as the selectable marker in these
transformations. The pma1 allele to be expressed was tagged
after codon 2 with either a sequence corresponding to a 10-amino acid
cMyc epitope plus linking sequences (MTASEQKLISEEDLNDTS) or
a 9-amino acid HA epitope (MTYPYDVPDYADTS) (25). To
generate a tagged version of LST1, the cMyc epitope was
inserted after codon 13, and this construct was introduced at the
LST1 genomic locus using integrative plasmid YIplac128
linearized with StuI. As shown in Table I, tagged versions
of pma1 were placed under control of a heat-shock promoter
(27) in integrative plasmid pRS303 (HIS3), YIplac128 (LEU2), or YIplac204 (TRP1) or centromeric
plasmid Ycplac22 (LEU2). Integrative plasmids were
linearized with NheI (pRS303), AflII (YIplac128),
or BsgI (YIplac204) and integrated at the genomic locus
corresponding to the selectable marker. The transformants were grown at
23 °C in synthetic complete medium (38) lacking uracil and the
relevant auxotrophic amino acids and containing 2% galactose. As
desired, expression of the GAL1-PMA1 copy was turned off by incubating the cells for 3 h in medium containing 2% glucose instead of galactose, and expression of the tagged PMA1 gene was induced by incubation of the cells at
39 °C.
Immunofluorescence--
Subcellular structures containing HA- or
cMyc-tagged ATPase were visualized by confocal microscopy as described
by DeWitt et al. (25). Cells were fixed, treated with
zymolyase T-100, permeabilized by Triton X-100, and stained for
immunofluorescence essentially as described by Redding et
al. (39) but with the addition of a blocking step in modified WT
buffer, in which the dry milk and bovine serum albumin were replaced by
5% normal goat serum (Sigma). Primary antibodies that were used
included: HA polyclonal (Medical and Biological Laboratories Co., Ltd.,
Nagoya, Japan), diluted 1:100; HA.11 monoclonal 16B12 and cMyc
monoclonal 9E10 from raw ascites fluid (Berkeley Antibody Co.,
Richmond, CA), diluted 1:150; V-ATPase 60-kDa subunit monoclonal
13D11-B2 from raw ascites fluid (Molecular Probes, Eugene, OR), diluted 1:150; Sec7 (large domain) and Sec12 polyclonal antibodies (provided by
R. Schekman (40)), diluted 1:150 and 1:100, respectively; and
Kar2 polyclonal antibody (provided by M. Rose (41)), diluted 1:2500.
Goat anti-rabbit FITC and goat anti-mouse Texas Red IgG (Jackson
Immunoresearch, West Grove, PA) served as fluorescent secondary
antibodies and were diluted 1:100. For double-labeling experiments,
both primary antibodies were present during the initial incubation, and
both secondary antibodies were present during the subsequent
incubation. To control for spurious cross-reactivity of the cMyc and HA
antibodies, uninduced cells were simultaneously fixed and stained with
each set of antibodies. Cells were then mounted in Citifluor (Ted
Pella, Reading, PA).
Cells were observed on a Zeiss L510 scanning confocal microscope using
dual channel filters for simultaneous visualization of Texas Red and
FITC fluorochromes. All images were taken with a 63 × 1.4 NA
Plan-Apochromat III DIC objective (Zeiss). In time-course experiments,
the exact same settings were used throughout the experiment to obtain a
semi-quantitative signal. Cross-talk between FITC and Texas Red was
avoided through the use of the Zeiss L510 digital signal processor. The
absence of bleed-through was confirmed by checking that the signal
disappeared when viewed with single-wavelength filter blocks. Images
were collected with LSM5 software (Zeiss) and modified by contrast
stretching, application of pseudocolor, and merging using Adobe
Photoshop 4.0 (Adobe Systems Inc., San Jose, CA).
Immunoelectron Microscopy--
Early logarithmic-phase cells
were collected on a 0.22-µm filter and transferred without washing to
3% paraformaldehyde (Electron Microscopy Sciences, Fort Washington,
PA), 0.04 M potassium phosphate, pH 6.7, 0.8 M
sorbitol, 1 mM MgCl2, and 1 mM
CaCl2. After fixation for 1 h at room temperature and
overnight at 4 °C, the cells were embedded in LR White resin
(Electron Microscopy Sciences) as described by Mulholland
et al. (42).
Ultrathin sections were cut using a Reichert FC4E ultramicrotome and
collected on Formvar/carbon-coated grids. Nonspecific binding sites
were quenched using 1% fish skin gelatin (Sigma) in phosphate-buffered
saline (PBS). The grids were incubated with anti-HA antibody (HA.11
monoclonal 16B12; Berkeley Antibody Co.) at a dilution of 1:40 in PBS,
1% fish skin gelatin, then washed in PBS and incubated with rabbit
anti-mouse antibody (Cappel, ICN Pharmaceutical, Aurora, OH) at a
dilution of 1:50. Finally, they were incubated with protein A-5-nm gold
complex (purchased from J. Slot, Utrecht, Netherlands) at a dilution of
1:70. After final washes in PBS, the sections were fixed for 5 min in
1% glutaraldehyde (Electron Microscopy Sciences) in PBS. The
sections were contrasted with 5% aqueous uranyl acetate and lead
citrate and examined in a Philips 410 electron microscope.
Isolation of Secretory Vesicles and Limited
Trypsinolysis--
Secretory vesicles were isolated from cells
carrying the temperature-sensitive sec6-4 mutation as
described previously (43) with the substitution of a multistep
discontinuous gradient for the two-step gradient used in the original
method. Cells grown to early logarithmic phase in synthetic complete
medium lacking uracil and tryptophan and containing 2% galactose were
shifted for 3 h to medium lacking galactose but containing 2%
glucose. The cells were then incubated for 2 h at 39 °C to
induce the expression of HA-tagged ATPase and the accumulation of
secretory vesicles. After conversion to spheroplasts (32) and
incubation with concanavalin A (0.8 mg/ml), the cells were broken by
Dounce homogenization and centrifuged for 10 min at 14,500 × g to remove concanavalin A-coated plasma-membranes,
mitochondria, and unbroken cells. The supernatant fraction (cell
lysate) was centrifuged for 35 min at 160,000 × g, and
the resulting pellet was suspended in 3 ml of 12.5% sucrose (w/v), 20 mM triethanolamine/acetic acid, pH 7.2, and 1 mM EDTA containing 1 mM diisopropyl
fluorophosphate, leupeptin (1 µg/ml), pepstatin (1 µg/ml),
aprotinin (1 µg/ml), and chymostatin (2 µg/ml). This fraction has
been shown in control experiments to contain little, if any,
plasma-membrane-associated ATPase. It was further fractionated by
loading 2 ml onto a discontinuous sucrose gradient (15-60%,
consisting of 2.7 ml of 15, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54,
60% (w/v) sucrose, each in 10 mM HEPES, pH 7.5, and 1 mM EDTA) and centrifuging at 100,000 g for 90 min.
Fractions were collected and analyzed by immunoblotting or enzyme
assays. Trypsinolysis experiments were carried out as described
by Nakamoto et al. (27), using a trypsin to protein ratio of
1:4.
Total Protein Extracts and Immunoblotting--
Total protein
extracts were prepared as described by Volland et al. (44).
Logarithmic-phase cells (A600 nm = 0.5) were suspended in 500 µl of water and broken by the addition of 50 µl of 1.85 M NaOH, 5% (v/v) -mercaptoethanol, and
proteins were precipitated by the addition of 50 µl of 50% (m/v)
trichloroacetic acid. The resulting pellets were resuspended in 10 µl
of 1 M Trizma (Tris base) and 20 µl of Laemmli SDS-PAGE
loading buffer (45), resolved on 10% polyacrylamide gels (SDS-PAGE),
and transferred to a polyvinylidene difluoride membrane. HA-tagged and
cMyc-tagged ATPases were quantitated by immunoblotting with rabbit
anti-cMyc or anti-HA polyclonal antibody (Medical and Biological
Laboratories, Nagoya, Japan), diluted 1/2000 and Kar2p by
immunoblotting with rabbit Kar2 polyclonal antibody (provided by M. Rose, 41), diluted 1/5000, followed by incubation with
125I-protein A and fluorography. For quantitative
immunoblotting of the HA-tagged ATPase in the sucrose gradient
fractions (see above), trichloroacetic acid-precipitated proteins from
100-µl samples were assayed in the same manner.
Enzyme Assays--
GDPase activity used as a Golgi marker was
measured according to Abeijon et al. (46). NADPH cytochrome
c oxidase served as an ER marker and was assayed by the
method of Feldman et al. (47). Assays of ATPase hydrolysis
and protein were carried out as described previously (48).
Immunoprecipitation and Detection of Ubiquitin-conjugated
ATPase--
Cells growing in selective synthetic complete medium
containing 2% galactose were induced to express wild-type or mutant
ATPase by heat shock at 39 °C as described above (see "Strains,
Plasmids, and Growth Conditions"). HA-tagged ATPase was
immunoprecipitated from solubilized yeast membranes using a
modification of the method described by Galan et al. (49).
Lysis buffer (0.1 M Tris-HCl, pH 7.5, 0.15 M
NaCl, 5 mM EDTA) included N-ethylmaleimide to 25 mM, phenylmethylsulfonyl fluoride to 0.5 mM,
and a mixture of leupeptin, aprotinin, pepstatin, and chymostatin (each
at 2 µg/ml final concentration). Cell homogenates, obtained by
vortexing cells with chilled glass beads, were centrifuged at 3,000 rpm in an Eppendorf microcentrifuge for 5 min at 4 °C. Supernatants were
collected and centrifuged at 14,000 rpm for 45 min. The
membrane-enriched pellets were resuspended in 0.5 ml TNET buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS) supplemented with the same protease inhibitors used above for the
lysis buffer. Insoluble aggregates were removed by centrifugation at
14,000 rpm for 45 min. Solubilized membranes were pre-cleared by adding
50 µl of protein A-Sepharose CL-4B (Amersham Biosciences)
equilibrated at 0.125 g/ml in 25 mM Tris-HCl, pH 7.4, 20 mM NaCl, 0.01% sodium azide, and incubating on a rotator at 4 °C for 90 min. The affinity matrix was removed by
centrifugation at 3,000 rpm for 5 min, then each cleared supernatant
received a fresh 50 µl of protein A-Sepharose CL-4B slurry along with
5 µl of either anti-HA (HA.11) monoclonal 16B12 or anti-cMyc
monoclonal 9E10 raw ascites fluid (Berkeley Antibody Co., Richmond,
CA). After overnight incubation at 4 °C, the affinity matrix was
recovered by centrifugation at 5,000 rpm and washed a total of four
times, twice with TNET, once with TNET containing 0.5 M
NaCl, and finally with TNET. Immunoprecipitates were recovered from the
affinity matrix by adding 50 µl of Laemmli SDS-PAGE loading buffer
and incubating at 30 °C for 15 min. Samples were separated on 8%
polyacrylamide gels and immunoblotted as described above. HA-tagged or
ubiquitinated proteins were detected using rabbit polyclonal antibodies
against the appropriate epitope followed by incubation with horseradish peroxidase-conjugated anti-rabbit antibodies. Immunoblots were developed using the ECL+ detection system (Amersham Biosciences).
Solubility of ATPase in 1% Triton X-100--
The solubility of
the ATPase in 1% Triton X-100 was assessed essentially as described by
Gong and Chang (50). Cells were lysed by vortexing with glass beads in
50 mM Tris-HCl, pH 7.5, containing 0.3 M
sucrose, 5 mM EDTA, 1 mM EGTA and supplemented with the same protease inhibitor mixture used for immunoprecipitation (see above). After centrifugation at 3,000 rpm for 5 min, a volume of
lysate supernatant equivalent to 5 A600 nm
units of cells was extracted with an equal volume of ice-cold 2%
Triton X-100 (v/v) and incubated on ice for 30 min. Samples were
centrifuged at 100,000 × g for 1 h, then pellets
(resuspended in 1% SDS) and supernatants were analyzed by
immunoblotting. HA-tagged wild-type and Pma1-G381A ATPases were
detected as described above (see "Total Protein Extracts and
Immunoblotting").
 |
RESULTS |
Expression and Subcellular Localization of Pma1-G381A--
To
track the biogenesis of Pma1-G381A, we modified an expression system
developed previously by Nakamoto et al. (32) in which the
wild-type PMA1 gene (which is required for growth (15)) is
placed under control of the inducible GAL1 promoter, and the mutant pma1 allele is introduced under control of a
heat-shock promoter (2HSE). Thus, expression can be switched
from the wild-type to the mutant ATPase by transferring the cells from
galactose medium at 23 °C to glucose medium at 39 °C. For the
present study, Pma1-G381A was tagged at the N-terminal end with an HA
epitope to follow the expression and subcellular localization of the
mutant ATPase (25). The tagged gene was cloned in-phase with the
2HSE promoter and integrated at the HIS3 locus to
give a homogeneous population of cells carrying a single copy of the
mutant allele. After growth on galactose medium at 23 °C, the
culture was transferred to glucose medium at 23 °C for 3 h to
turn off expression of the wild-type gene and empty the secretory
pathway of the corresponding protein. At that point (defined as time
zero), the culture was incubated for 15 min at 39 °C to induce a
short pulse of Pma1-G381A-HA synthesis and then returned to 23 °C.
As a control, a parallel experiment was carried out with cells in which
HA-tagged wild-type PMA1 had been integrated at the
HIS3 locus, again under control of the 2HSE promoter.
To track the time course of expression under these conditions, total
protein extracts were prepared at intervals and immunoblotted with
anti-HA polyclonal antibody. As shown in Fig.
1A, the wild-type form was
expressed maximally by 15 min of incubation at 39 °C and remained
fully stable for at least 240 min. Pma1-G381A was also readily
detectable at 15 min and rose slightly by 30 min, but it then decayed
with a half-life of ~60 min, as estimated by quantitative
densitometry. The degradation pathway for the mutant form is discussed
in a later section.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 1.
Expression and subcellular localization of
the wild-type and Pma1-G381A ATPases as a function of time. WG4a
WT-HA and WG4a G381A-HA cells were grown to early logarithmic phase in
medium containing 2% galactose at 23 °C and transferred for 3 h to medium containing 2% glucose to repress expression of the
untagged Pma1 ATPase. The cells were then shifted to 39 °C at
t = 0 min to induce expression of the HA-tagged form
and returned to 23 °C at t = 15 min. A, total
protein extracts were prepared as described under "Experimental
Procedures," subjected to SDS-PAGE, immunoblotted with polyclonal HA
antibody, and detected by 125I-protein A and
autoradiography. B, cells were fixed with formaldehyde and
processed for immunofluorescence using anti-HA monoclonal antibodies
and Texas Red-conjugated goat anti-mouse IgG, as described under
"Experimental Procedures." At each time point, the same field of
cells was analyzed by confocal microscopy under exactly the same
conditions to obtain a semi-quantitative signal. Bar, 5 µm.
|
|
Another striking difference between the wild-type and mutant forms
became apparent when confocal microscopy was used to localize the
HA-tagged proteins within the cell. As shown in Fig. 1B
(upper panels), the wild-type form could be detected as a
diffuse signal, spread throughout the cytoplasm at 30 min after
induction; most of the signal had reached the plasma membrane by 60 min
and was still visible there at 180 min. Thus, the tagged wild-type
ATPase appears to move smoothly through the secretory pathway, with no obvious retention in any intracellular compartment. By contrast, Pma1-G381A accumulated in punctate intracellular structures, which could be seen as early as 30 min and were very prominent at 60 min
(Fig. 1B, lower panels). By 120 min, most of the
punctate structures had disappeared, and Pma1-G381A was clearly visible at the plasma membrane. By 180 min, consistent with the results in Fig.
1A, the mutant form could barely be detected.
The results presented in Fig. 1 illustrate two clear abnormalities in
expression of the G381A ATPase; they are a transient intracellular
accumulation and an accelerated rate of degradation once it reached the
plasma membrane. To ensure that neither abnormality was simply a
consequence of the short incubation at 39 °C needed to activate the
2HSE promoter, control experiments were carried out using a
different promoter (GAL1), which does not permit the same
time resolution but can be activated at 23 °C by transferring cells
to galactose as sole carbon source. Cells carrying
GAL1pr-HA-G381A on a centromeric plasmid (25)
were grown on 4% raffinose and then transferred to medium containing
4% galactose to induce expression of the ATPase. Once again, confocal
microscopy revealed prominent intracellular punctate bodies at 60-120
min in cells expressing G381A but not in the wild-type control.
Furthermore, when the GAL1 promoter was turned off by
transferring the cells to 3% glucose, immunoblot analysis of total
protein extracts showed once again that the G381A-HA ATPase decayed
much more rapidly than its wild-type counterpart, with little or no
mutant ATPase visible by 180 min (not shown). Thus, both the transient
intracellular accumulation and the rapid degradation appear to be
properties inherent to the mutant polypeptide, independent of the brief
heat shock used in the experiment of Fig. 1.
Pma1-G381A Is Arrested Transiently in the ER but Does Not Stimulate
the Unfolded Protein Response--
To pinpoint the compartment in
which the mutant ATPase is transiently retained, confocal microscopy
was used to compare the localization of the ATPase with that of ER and
Golgi markers. At 60 min post-induction, as shown in Fig.
2, A and B, the
intracellular Pma1-G381A signal was coincident with that of Kar2p (a
specific ER marker (41)) but not with that of Sec7p, a late Golgi
marker (40). It was not possible to visualize two other ER
membrane-associated proteins, Sec12p (a guanine nucleotide exchange
factor (51)) and Lst1p (a plasma membrane
H+-ATPase-specific homolog of Sec24p (52)) at the same time
point, presumably because protein levels were too low or the proteins were too dispersed to detect by confocal microscopy (not shown). At 15 min post-induction, however, Lst1-cMyc co-localized in small regions of
punctate labeling with both wild-type and mutant forms of the ATPase
(Fig. 2, C and D); given the early time at which these structures were observed, they may represent specific sites of
ATPase incorporation into specialized COPII vesicles.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Delayed export of Pma1-G381A mutant from the
ER. WG4a G381A-HA cells were treated as described in the legend to
Fig. 1 and fixed with formaldehyde at t = 60 min
following heat-shock induction. The cells were processed for
double-label immunofluorescence as described under "Experimental
Procedures" using antibodies to HA (left panels) combined
with antiserum to either Kar2p (A) or Sec 7p (B)
(middle panels) and detected by FITC- and Texas
Red-conjugated secondary antibodies. To assess their COPII
vesicle-packaging behavior, mutant and wild-type ATPases were tested
for co-localization with Lst1p. Cells of strains BMY451 and BMY452 were
treated as described in the legend of Fig. 1. Immediately before and at
various time points after induction at 39 °C, 5-ml aliquots were
processed for confocal microscopy as described above. Panels
C and D show Pma1-G381A-HA and wild-type-HA ATPases,
respectively, detected 15 min post-induction using rabbit polyclonal
anti-HA antibodies and Texas Red-conjugated secondary antibodies.
Lst1p-cMyc was detected with rabbit polyclonal anti-cMyc antibodies and
FITC-conjugated secondary antibodies. Staining of both fluorochromes
was visualized simultaneously by confocal microscopy using dual channel
filters, and the images were merged using Adobe Photoshop (right
panels). Bars, 5 µm.
|
|
At later times, the morphology of the ER became severely altered during
Pma1-G381A expression. In the experiment of Fig.
3A, cells producing either
wild-type or mutant ATPase were compared at 60 and 120 min after
induction. At both time points, cells expressing wild-type ATPase
showed Kar2p labeling surrounding the nucleus, with distinct extensions
to the cell periphery, consistent with the typical pattern for yeast ER
(53). By contrast, in cells expressing the mutant ATPase, Kar2p first
co-localized in peripheral punctate structures with Pma1-G381A (Fig.
3A, 60 min). By 120 min, when Pma1-G381A had finally reached
the plasma membrane, the punctate bodies had largely disappeared, and
Kar2p was again distributed in the normal ER pattern.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3.
Subcellular localization of HA-tagged ATPase
and Kar2p/BiP as a function of time. WG4a WT-HA and WG4a G381A-HA
cells were treated as described in the legend to Fig. 1. A,
the cells were fixed with formaldehyde at t = 60 min or
120 min after heat-shock induction, processed for double-label
immunofluorescence as described in the legend to Fig. 2 using
antibodies to HA (top panels) combined with antiserum to
Kar2p (middle panels), and detected by FITC- and Texas
Red-conjugated secondary antibodies. Merged images are displayed in the
bottom panels. Bar, 5 µm. B, total
protein extracts were prepared and analyzed as described in the legend
to Fig. 1. Symbols are as follows: filled circles and
filled squares, WG4a WT-HA blotted with HA antiserum and
Kar2p antiserum, respectively; open circles and open
squares, WG4a G381A-HA, blotted with HA antiserum and Kar2p
antiserum, respectively. Detection was by 125I-protein A
and autoradiography.
|
|
There is abundant evidence that Kar2p/BiP functions as a molecular
chaperone during ER quality control (reviewed by Gething (54)); indeed,
Kar2p/BiP is frequently overexpressed as part of the "unfolded
protein response" that is triggered by the accumulation of poorly
folded proteins in the ER (55, 56). To test whether Pma1-G381A
stimulates the expression of Kar2p, quantitative immunoblotting was
carried out on total protein extracts. As shown in Fig. 3B, there was no significant rise in the level of Kar2p in
Pma1-G381A-expressing cells at 60 min (when the punctate bodies were
most prominent) nor did Kar2p fall at 120 min (when the punctate bodies
had disappeared). Thus, the morphological changes seen in Fig.
3A represent a redistribution of Kar2p, with no detectable
change in its amount.
Proliferation of Specific Membrane Compartments in Cells Expressing
Pma1-G381A--
As a follow-up to confocal microscopy results (Figs.
1-3), electron microscopy was carried out to explore the nature of the abnormal structures observed in cells expressing Pma1-G381A. Fig. 4, A-E, reveals a pronounced
swelling of the ER lumen at 60 min, similar to that seen when a
temperature-sensitive mutation such as bet1-3 blocks the
secretory pathway between the ER and Golgi (57). Even more striking
were the conspicuous clusters of vesicular and tubular elements, which
appeared to form a network continuous with the peripheral ER (Fig. 4,
A-E). These clusters had a similar morphology in all cells
expressing Pma1-G381A, but they varied in size from discrete structures
located mainly at the cell periphery (seen in most cells;
e.g. Fig. 4, A and C) to larger
structures that invaded much of the cytoplasm (seen in 10-30% of the
cells; Fig. 4E). Immunogold staining confirmed that they
contained both Pma1-G381A (Fig. 4, A-E) and Kar2p/BiP (not
shown). Significantly, the clusters were much smaller and less numerous
in cells expressing wild-type ATPase (Fig. 4F), and they
disappeared almost completely after 2 h in cells expressing
Pma1-G381A. Taken together, the results suggest that this transiently
formed compartment may be the place at which Pma1-G381A exits the ER;
thus, it may be equivalent to the vesicular-tubular clusters (VTCs)
that constitute an ER-to-Golgi intermediate compartment in mammalian
cells (58, 59).

View larger version (107K):
[in this window]
[in a new window]
|
Fig. 4.
Immunoelectron micrographs of cells
expressing G381A or wild-type ATPases. WG4a G381A-HA cells
(A-E) and WG4a WT-HA cells (F) were incubated as
in the experiment of Fig. 2, fixed with 3% paraformaldehyde at
t = 60 min, and embedded in LR-white as described under
"Experimental Procedures." Thin sections were incubated with
antibodies to HA, incubated with rabbit anti-mouse antibody, and
finally incubated with colloidal gold-conjugated protein A. B and D are magnifications of the regions
boxed in A and C, respectively, where
clusters of gold particles were observed (arrows).
Circles and ovals indicate other regions of gold
particle clustering. N, nucleus. Bars, 1 µm
(A, C, E, F) or 0.25 µm
(B, D).
|
|
Pma1-G381A Avoids ER-associated Protein Degradation and Escapes
from the ER--
ER-associated protein degradation is a well
characterized pathway that involves retro-translocation of misfolded
proteins from the ER into the cytoplasm, multi-ubiquitination (1, 3), and digestion by the proteasome (2). In the case of Pma1-G381A, which
can reach the plasma membrane (Fig. 1), this pathway might be
considered unlikely. It seemed important, however, to examine the
possibility that part of the Pma1-G381A population might be targeted
directly for degradation by the proteasome after transient retention in
the vesicular-tubular compartment. For this purpose, Pma1-G381A was
expressed in a pre1-1, pre2-2 mutant strain that lacks the
chymotrypsin-like activity of the proteasome (60). Such a strain
displays enhanced sensitivity to stress conditions such as prolonged
heat shock or treatment with canavanine, a toxic amino acid analog that
causes the accumulation of unfolded proteins (60). In the experiment of
Fig. 5A, pre1-1,
pre2-2 or normal cells were grown at 23 °C, pretreated
with canavanine (20 µg/ml) for 90 min, transferred to 39 °C for 15 min to induce the expression of HA-tagged Pma1-G381A ATPase, and then
returned to 23 °C. At intervals, total protein extracts were
prepared and assayed for HA-tagged ATPase by quantitative
immunoblotting. As shown in Fig. 5A, the pre1-1,
pre2-2 double mutation had no detectable effect on the time
course of degradation of Pma1-G381A. Moreover (not shown), there was no
change in time course when Pma1-G381A was expressed in cells carrying a
deletion of UBC1, which encodes one of the two major
ubiquitin-conjugating enzymes of the ER-associated protein degradation
pathway (4). These findings argue against a significant role for the
proteasome in the degradation of Pma1-G381A.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 5.
Pma1-G381A is not degraded by the
proteasome. A, WG4a G381A-HA (filled
circles) and WG4a-11/22a G381A-HA (open circles) cells
were grown to early logarithmic phase in medium containing 2%
galactose at 23 °C and transferred for 1.5 h to medium
containing 2% glucose. Canavanine was added to the culture (20 µg/ml), and incubation was continued for 1.5 h. Expression of
the HA-tagged ATPase was induced by shifting the cells to 39 °C for
15 min. Total protein extracts were prepared as described under
"Experimental Procedures," subjected to SDS-PAGE, immunoblotted
with antiserum to HA, and detected by 125I-protein A and
autoradiography. B, BMY401 (WT) and BMY402 (G381A) cells
were grown as for strains described in the legend of Fig. 1.
Immediately before induction of expression (t = 0) and
at 30-min intervals thereafter, 25-ml samples of cells were harvested
and lysed, and the plasma membrane H+-ATPase was
immunoprecipitated from detergent-solubilized membranes as described
under "Experimental Procedures." The 100-kDa HA-tagged ATPase was
detected in samples equivalent to 0.5 A600 units
of cells (1×) by Western blotting using rabbit anti-HA antibody. By
contrast, ubiquitinated (Ub) forms of ATPase, identified
using rabbit anti-ubiquitin antibody, were detected only when protein
samples equivalent to 15 A600 units of cells
(30×) were loaded. Blots were developed using horseradish
peroxidase-conjugated anti-rabbit antibodies and the ECL+Plus
chemiluminescent detection system (Amersham Biosciences).
|
|
Independent evidence came from experiments designed to detect
ubiquitinated forms of wild-type or Pma1-G381A ATPase. For this purpose, HA-tagged ATPase was immunoprecipitated with anti-HA monoclonal antibodies at various time points after heat-induced expression and then analyzed for modification by immunoblotting with
anti-ubiquitin polyclonal antibodies. Ubiquitinated forms of ATPase
were detected only when the amounts of immunoprecipitate loaded were
increased 30-fold (see Fig. 5B legend); although this result
probably indicates a low level of protein ubiquitination, it may also
reflect differences in the reactivities of anti-HA and anti-ubiquitin
polyclonal antibodies. Such differences can be corrected for by
considering ubiquitin-to-ATPase ratios. As shown in Fig. 5B,
the ubiquitin-to-ATPase ratio was similar in both wild-type and
Pma1-G381A ATPases, and the ratio decreased as a function of
time, suggesting early ubiquitination may simply reflect a low basal
level of protein misfolding. These results provide added evidence
against a quantitatively significant role for ER-associated protein
degradation in Pma1-G381A degradation.
Appearance of Misfolded Pma1-G381A in the Secretory
Vesicles--
The next step was to look directly at the folding of
Pma1-G381A ATPase that has left the ER and is moving toward the plasma membrane. For this purpose, secretory vesicles were isolated from sec6-4 cells expressing either wild-type or G381A ATPase.
Cells were heat-shocked for 2 h to induce ATPase expression and
the accumulation of secretory vesicles, and the vesicles were isolated by differential centrifugation followed by centrifugation on a multi-step discontinuous gradient. Immunoblotting revealed a prominent peak of HA-tagged ATPase in fraction 8 of the wild-type gradient and a
slightly broader peak in fractions 8-10 of the Pma1-G381A gradient
(Fig. 6, A and B).
Control experiments established that this peak corresponded to the
secretory vesicles, since it was not seen in cells carrying a normal
copy of the SEC6 gene (not shown). Wild-type ATPase was
fully active in the secretory vesicles, confirming an earlier
observation by Nakamoto et al. (32), but Pma1-G381A lacked
measurable ATPase activity (see the legend to Fig. 6). In both cases,
there was little if any contamination of the secretory vesicle fraction
by ER or Golgi, for which NADPH-cytochrome c reductase and
GDPase served as markers (Fig. 6, A and B).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 6.
Purification of secretory vesicles and
limited trypsinolysis of WT and G381A ATPases. TFY15 WT-HA
(A) and TF15 G381A-HA cells (B) were grown to
early logarithmic phase in medium containing 2% galactose at 23 °C
and transferred for 3 h to medium containing 2% glucose. Cells
were then incubated at 39 °C to induce the expression of HA-tagged
ATPase and the accumulation of secretory vesicles. After 2 h,
plasma membrane-free fractions were prepared as described under
"Experimental Procedures" and subjected to sucrose gradient
centrifugation. Fractions were collected and immunoblotted with
antiserum to HA (filled circles) or assayed for ATPase
(open squares), NADPH cytochrome c reductase
(filled squares), and GDPase (open circles).
Results are expressed as a percentage of the total activity loaded onto
the gradient; for TFY15 WT-HA, ATPase activity = 56.9 units, NADPH
cytochrome c reductase activity = 5.6 units, and GDPase
activity = 28.7 units; for TFY15 G381A-HA, ATPase activity = 2.0 units, NADPH cytochrome c reductase activity = 6.2 units, and GDPase activity = 35.7 units. C, purified
secretory vesicles (25 µg) obtained from fractions 7 and 8 of TFY15
WT-HA (WT-HA) cells and fractions 8 and 9 of TF15 G381A-HA (G381A-HA)
cells were incubated at a trypsin:protein ratio of 1:4 for 0, 0.5, 2, 5, and 10 min. The specific ATPase activities of these fractions were
4.65 units/mg and 0.17 units/mg for TFY15 WT-HA and TFY15 G381A-HA.
Samples were subjected to SDS-PAGE, immunoblotted with antiserum to
Pma1p, and detected by 125I-protein A and
autoradiography.
|
|
In the experiment of Fig. 6C, fractions 7 and 8 from the
wild-type gradient and fractions 8 and 9 from the Pma1-G381A gradient were incubated with a low concentration of trypsin to compare the
folding of the wild-type and mutant ATPases in the secretory vesicles.
As in previous studies, the wild-type ATPase was degraded slowly, with
the transient appearance of 96-, 72-, and 62-kDa bands; even after 10 min, a considerable amount of the 62-kDa fragment could still be seen.
By contrast, Pma1-G381A was extremely sensitive to trypsin, as reported
previously for assays of total membrane fractions (25); the 96-kDa band
disappeared rapidly after the 0.5-min time point, and smaller fragments
were not detectable. Thus, it seems clear that Pma1-G381A is still
poorly folded when it reaches the secretory vesicles.
Degradation of PMA1-G381A after Arrival at the Plasma
Membrane--
Is Pma1-G381A targeted to the vacuole for degradation,
and does this occur before or after fusion of the secretory vesicles with the plasma membrane? We addressed these questions by asking whether the mutant ATPase is protected by temperature-sensitive blocks
introduced at the latter stages of the export pathway. As shown in Fig.
7A, Pma1-G381A degradation was
slowed markedly in cells bearing either the temperature-sensitive
sec6-4 mutation (to interrupt fusion of the secretory
vesicles with the plasma membrane (61)) or a temperature-sensitive
end4 mutation (to interrupt endocytosis from the plasma
membrane (29)). Furthermore, as shown in Fig. 7B, Pma1-G381A
degradation was also inhibited fully in cells carrying a
pep4 deletion, which eliminates the aspartyl protease
(proteinase A) that is required for post-translational activation of
vacuolar hydrolases (62). In parallel, confocal microscopy was used to
examine the localization of Pma1-G381A after a 180-min incubation in
pep4 cells (Fig. 7C). Under these conditions,
HA-tagged Pma1-G381A could be seen clearly in the plasma membrane and
the vacuole, whereas in the PEP4 control strain, it had
disappeared completely from the cell. As expected, HA-tagged wild-type
ATPase maintained a stable association with the plasma membrane, even
in the pep4 strain.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 7.
Pma1-G381A degradation occurs in the vacuole
only after prior targeting to the plasma membrane. A,
TF32 G381A-HA (filled circles), TF15 G381A-HA (open
circles), and TF1 G381A-HA cells (open squares) were
treated as described in the legend to Fig. 1 except that the
temperature was maintained at 39 °C from t = 0 min.
Total protein extracts were separated by SDS-PAGE, immunoblotted with
antiserum to HA and detected by 125I-protein A and
autoradiography. W303-1B/D G381A-HA (filled circles) and
W303-1B-pep4 G381A-HA (open circles) cells were treated
as described in the legend to Fig. 5. B, total protein
extracts were subjected to SDS-PAGE, immunoblotted with antiserum to
HA, and detected by 125I-protein A and autoradiography.
C, W303-1B-pep4 G381A-HA (upper panels) and
W303-1B/D G381A-HA cells (middle panels) were fixed with
formaldehyde at t = 180 min and processed for
double-label immunofluorescence as described under "Experimental
Procedures" using antiserum to HA (left panels), combined
with antibodies to the 60 kDa V-ATPase subunit (middle
panels), and detected by FITC- and Texas Red-conjugated secondary
antibodies. As a control, W303-1B-pep4 WT-HA cells (lower
panels) were fixed and processed for immunofluorescence under the
same conditions. Merged images are displayed in the right
panels. Staining and visualization were as in the legend to Fig.
2. Bar, 5 µm.
|
|
Taken together, the results described up to this point indicate that
the bulk of misfolded Pma1-G381A is not sent from the ER for
degradation in the proteasome; rather, it progresses via the secretory
vesicles to the plasma membrane, where a different quality control
system dictates its removal by endocytosis and delivery to the vacuole
for degradation. One way for such a system to recognize the misfolded
mutant ATPase is suggested by the recent finding that wild-type Pma1
becomes associated with glycosphingolipid- and ergosterol-containing
lipid rafts en route to the cell surface (63). If Pma1-G381A
failed to enter lipid rafts, it could conceivably be more vulnerable to
the endocytic process, as has recently been reported for another Pma1
mutant (Pma1-10 (50)).
To explore this possibility, we assayed total cell lysates for the
solubility of Pma1 ATPase in 1% Triton X-100 and found that, like the
wild-type ATPase, Pma1-G381A was not extracted into the supernatant
under these conditions at any of the time points tested (Fig.
8). Thus, by contrast with Pma1-10,
Pma1-G381A appears to be able to associate with lipid rafts, at least
as measured by the standard Triton insolubility assay. Further work will be required to learn whether this association is completely normal
or whether it may be altered in some way that makes the mutant ATPase a
target for the endocytic machinery.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 8.
Pma1-G381A is insoluble in 1% Triton
X-100. Strains BMY401 (WT) and BMY402 (G381A) were grown as
described in legend of Fig. 1. Immediately before induction
(t = 0) and at 60 and 120 min thereafter, protein
lysates were made from 25-ml cell samples (see "Experimental
Procedures"). After extraction with 1% Triton X-100 and
centrifugation at 100,000 × g, supernatant
(S) and pellet (P) fractions representing 25% of
total sample (i.e. 5 A600 units
cells) were immunoblotted to detect HA-tagged WT or Pma1-G381A ATPase
using polyclonal anti-HA antiserum.
|
|
Effects of Pma1-G381A on Co-expressed Wild-type ATPase--
In the
study by DeWitt et al. (25), the G381A mutation was shown to
behave in a co-dominant fashion, slowing but not preventing the growth
of cells that were also expressing wild-type ATPase. To explore the
mechanism of co-dominance in the light of the new information
(described above) on Pma1-G381A biogenesis, the wild-type and mutant
forms were epitope-tagged with cMyc and HA, respectively, placed under
control of the 2HSE promoter, and chromosomally integrated at the HIS3 and LEU2 loci. Expression of both was
induced simultaneously by means of a 15-min incubation at 39 °C.
Under these conditions, the wild-type and mutant ATPases co-localized
in punctate bodies at the 60-min time point, indicating that the
biogenetic phenotype of the Pma1-G381A mutation was imposed on the
wild-type ATPase (Fig. 9). This was not
simply a consequence of ATPase overexpression, since no intracellular
retention was observed in control cells expressing both cMyc- and
HA-tagged wild-type ATPase under the same conditions (not shown). As
described for cells expressing the mutant form alone, the locations of
Pma1-G381A and wild-type ATPase changed as a function of time,
progressing from the ER at 60 min to the plasma membrane at 180 min.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 9.
Co-localization of the Pma1-G381A mutant with
the wild-type ATPase. WG4a G381A-HA/WT-cMyc cells were treated as
described in the legend to Fig. 1. Co-expression of the cMyc-tagged
wild-type form (WT-cMyc) and the HA-tagged Pma1-G381A mutant form
(G381A-HA) was induced by shifting the cells to 39 °C for 15 min.
The cells were fixed with formaldehyde and processed for double-label
immunofluorescence as described under "Experimental Procedures"
using anti-HA (top panels) and anti-cMyc (middle
panels) and detected by Texas Red- and FITC-conjugated secondary
antibodies, respectively. Staining and visualization were as in the
legend to Fig. 2. Bar, 5 µm.
|
|
The clear effect of Pma1-G381A on the biogenesis of the wild-type
ATPase made it important to ask whether there was also an effect on
degradation. Figs. 10, A and
B, present the results of an immunoblotting experiment
designed to answer this question. In fact, although there was no
significant degradation of the wild-type ATPase when HA-tagged and
cMyc-tagged versions were expressed together over a 180-min time course
(panel A), cMyc-tagged wild-type ATPase was significantly
degraded when co-expressed with HA-tagged Pma1-G381A (panel
B). Quantitative densitometry gave rate constants of 60 min 1 for both forms, essentially identical to the
rate constant for Pma1-G381A when expressed alone (see Fig. 1).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 10.
Degradation of the wild-type ATPase induced
by Pma1-G381A. WG4a WT-HA/WT-cMyc (A) and WG4a
G381A-HA/WT-cMyc (B) cells were grown and treated as
described in the legend to Fig. 1. Total protein extracts were prepared
as described under "Experimental Procedures" subjected to SDS-PAGE,
immunoblotted with antisera to HA or to cMyc, and detected by
125I-protein A and autoradiography. C, total
proteins were extracted from TF32 G381A-HA/WT-cMyc cells (filled
squares and filled circles) or TF15 G381A-HA/WT-cMyc
cells (open squares and open circles) treated as
described above, except that the 39 °C heat-shock was maintained
from t = 0. After separation by SDS-PAGE, the samples
were immunoblotted with antisera to HA (open squares and
filled squares) or to cMyc (open circles and
filled circles) and detected by 125I-protein A
and autoradiography. D, WG4a G381A-HA/WT-cMyc cells were
grown in the conditions described in A in the absence
(filled squares and filled circles) or the
presence (open squares and open circles) of 4%
ethanol (v/v) added before heat-shock induction. Total protein extracts
were subjected to SDS-PAGE, immunoblotted with antisera to HA
(open squares and filled squares) or to cMyc
(open circles and filled circles) and detected by
125I-protein A and autoradiography.
|
|
Once again, the co-degradation of the Pma1-G381A and wild-type forms
required delivery to the plasma membrane followed by endocytosis.
Degradation was fully inhibited when both forms were expressed in a
sec6-4 background to block fusion of the secretory vesicles
with the plasma membrane (Fig. 10C) or when endocytosis was
blocked by the addition of 4% ethanol to the culture before induction
(Fig. 10D; Ref. 64). Thus, just as it affects the biogenesis of the wild-type ATPase, Pma1-G381A can also impose its degradation phenotype on the wild-type form.
 |
DISCUSSION |
In this study, a misfolded mutant of the Pma1
H+-ATPase has been used to explore quality control
mechanisms in the yeast secretory pathway. The mutant protein,
Pma1-G381A, behaves in a highly distinctive way at two different points
along the pathway; first, at the ER-to-Golgi transition, where it is
retained transiently in Kar2p-containing vesicular and tubular bodies
but avoids any significant level of degradation, and later, at the
plasma membrane, where it is removed rapidly by endocytosis and
delivered to the vacuole for degradation (see Fig.
11). Both steps provide insights into
the functioning of the secretory pathway and will be discussed in turn.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 11.
Transport and processing of the misfolded
H+-ATPase mutant Pma1-G381A. See "Results"
for a description of the mutant backgrounds used to define the pathway
of Pma1-G381A degradation. PM, plasma membrane;
SV, secretory vesicles. For a recent review of yeast plasma
membrane H+-ATPase biogenesis, see Ferreira et
al. (65).
|
|
Transient Retention of Pma1-G381A in the ER--
At the outset of
this work, there was already abundant evidence that the yeast ER can
proliferate abnormally when membrane trafficking is "jammed,"
either by excessive amounts of a normal cargo protein (e.g.
Refs. 66-68) or by synthesis of a defective (24-27) or heterologous
(69-78) cargo protein that fails to escape from the ER. ER-derived
structures also accumulate when ER-to-Golgi transport is blocked by
overexpressing Sec12p (79). Depending upon the specific experimental
conditions, the structures described by other authors have ranged from
stacks of membranes closely associated with the nuclear envelope
(termed "karmellae" by Wright et al. (66)) to
"sausage-like" bodies (67, 77, 78) and "BiP bodies" (79) that
are more widely dispersed in the cytoplasm. Karmellae probably arise
from a block in trafficking at a relatively early point in the
secretory pathway, whereas sausage-like structures and BiP bodies may
reflect a later block at or near the point of exit from the ER (79).
The results of the present study reinforce the position that BiP bodies
may be associated with the exit process. Most of the cells (70-90%)
expressing the Pma1-G381A mutant ATPase-formed punctate,
Kar2p-containing structures that were shown by electron microscopy to
consist of vesicular and tubular elements, derived from (and sometimes
still physically connected to) the peripheral ER. Significantly, these
structures formed only transiently; when Pma1-G381A escaped from the ER
and moved toward the plasma membrane, the ER recovered a characteristic
ring-like shape around the nucleus. It seems likely that these
ER-derived BiP bodies are analogous to the mammalian cell VTCs
described by Balch and co-workers (58, 59), which comprise a dynamic
ER-Golgi intermediate compartment (ERGIC) that is visible even under
normal conditions (80). By contrast, the ability to see VTCs in
yeast required perturbation of the secretory pathway by expression of
Pma1-G381A. Under normal circumstances, there is no obvious spatial
differentiation of the secretory pathway in S. cerevisiae;
instead, transitional vesicles bud throughout the ER, and Golgi
cisternae are scattered throughout the cytoplasm (81).
Recent evidence suggests that selective processes are operating during
export from the ER and that at least some cargo proteins, including
Pma1p (52) and the glycophosphatidylinositol-anchored protein
Gas1 (82), are incorporated into distinct subsets of COPII transport
vesicles. Thus, the proliferative regions of peripheral ER defined by
the delayed exit of Pma1-G381A may reflect the presence of an export
subdomain. The brief but highly localized coincidence of both WT and
mutant ATPases with Lst1p at only 15 min after induction and before
accumulation of Pma1-G381A in BIP bodies may represent exit sites that
are utilized preferentially by the plasma membrane
H+-ATPase for loading into COPII vesicles (Fig. 2,
C and D).
Because the mutant ATPase showed an Lst1p labeling pattern and time
course very similar to that of the wild-type protein, it seems unlikely
that Pma1-G381A is grossly aberrant in its vesicle-packaging behavior.
Furthermore, the apparently normal association of Pma1-G381A with lipid
rafts (Fig. 8) suggests that its subsequent passage to the plasma
membrane is comparable with that of the wild-type ATPase.
At the molecular level, it is not surprising that Pma1-G381A is
recognized in the ER as an incorrectly folded protein, since in
vitro experiments show it to be cleaved by trypsin under
conditions that leave wild-type H+-ATPase intact (25).
However, the structural defect in Pma1-G381A is less severe than in
many other misfolded H+-ATPase mutants, which are degraded
almost instantaneously by trypsin under the same conditions (25, 27).
The intermediate nature of the defect may explain why Pma1-G381A causes
VTCs to proliferate and Kar2p/BiP to be redistributed without
triggering a typical unfolded protein response. In particular, if
Pma1-G381A is not sufficiently unfolded to bind Kar2p/BiP, it may not
bring about the decrease in free lumenal concentration of Kar2p/BiP that is believed to be necessary for a fully fledged unfolded protein
response (reviewed in Refs. 6 and 55). This, in turn, may underlie the
eventual escape of Pma1-G381A from the quality control machinery of the
ER.
Retrieval of Pma1-G381A from the Plasma Membrane and Degradation in
the Vacuole--
At the plasma membrane, Pma1-G381A falls prey to
another as yet uncharacterized quality control system that recognizes
the mutant polypeptide as abnormal and sends it to the vacuole for degradation. Evidence for the re-direction of Pma1-G381A to the vacuole
via the plasma membrane comes from the clear-cut protection conferred
upon Pma1-G381A by mutations blocking secretory vesicle fusion with the
plasma membrane (sec6), endocytosis (end4), or vacuolar aspartyl protease activity (pep4 ). The end
result is a much reduced half-life of the Pma1-G381A mutant protein
(ca.1 h) compared with the wild-type Pma1 ATPase (>11 h;
Ref. 83) at the plasma membrane. Thus, once delivered to the cell
surface, Pma1-G381A follows the pathway of short-lived plasma-membrane proteins that are down-regulated by endocytosis (reviewed by Hicke (11,
12)).
Work in other laboratories has shown that the wild-type Pma1 ATPase can
be artificially targeted to the vacuole in at least two ways; they are
by adding either the PEST-like sequence of Ste3p, the yeast
a-factor receptor (84), or the linker region of the ABC-transporter
Ste6p (85). In both cases, ubiquitination has been suggested to play a
role in the degradative pathway, since prominent higher molecular
weight ATPase bands could be seen upon immunoblotting and increased in
amount when endocytosis was blocked in an end4 strain.
By contrast, ubiquitination appears not to be responsible for the
endocytosis and vacuolar degradation of the Pma1-G381A ATPase. Ubiquitinated forms were difficult to detect in the present study; they
appeared at a very low level almost immediately after induction and
then decreased over time. Furthermore, there was no appreciable difference in the amount or time course of ubiquitination between Pma1-G381A and the wild-type control. Thus, it seems likely that the
modification by ubiquitin occurs before or during transit of the ATPase
from ER-to-Golgi rather than at the plasma membrane and that it
reflects a low basal level of unfolding seen in a minor fraction of
newly synthesized ATPase. Small amounts of ubiquitinated wild-type
Pma1p were observed in the earlier study by Kolling and Losko (85) and
may have the same explanation.
Gong and Chang (50) recently described a temperature-sensitive
H+-ATPase mutant, Pma1-10, which was degraded after less
than 30 min at the plasma membrane. Like Pma1-G381A, Pma1-10 can be
protected by expression in sec6-4 or end4-1
cells, indicating that it is removed from the plasma membrane by
endocytosis before degradation. Pma1-10 is soluble in Triton X-100
and, thus, appears unable to associate successfully with lipid rafts;
the authors have proposed that this defect may underlie its instability
at the plasma membrane. By contrast, Pma1-G381A is insoluble in 1%
Triton X-100 (Fig. 8), suggesting that another mechanism must exist to
discriminate between wild-type and G381A ATPases at the plasma
membrane. This ultimate quality control step may involve interactions
with other proteins that serve to stabilize Pma1p at the cell surface
in a manner analogous to that by which spectrin stabilizes the
Na,K-ATPase of epithelial cells (86, 87). Mop2p (End4p/Sla2p) has been shown previously to regulate the amount of wild-type ATPase at the
plasma membrane; indeed, Mop2p overexpression can even allow for
overexpression of an otherwise toxic level of Pma1p (88). Because the
N-terminal and central coiled-coil domains of Mop2p/End4p are required
for endocytosis and interaction with actin-associated proteins (89), it
seems plausible that Mop2p could play a dual role in facilitating both
the insertion and the removal of Pma1p from the yeast plasma membrane.
Effect of Pma1-G381A on the Biogenesis and Degradation of Wild-type
Pma1 ATPase--
Finally, this work has shown that Pma1-G381A severely
affects the biogenesis of co-expressed wild-type ATPase, causing the wild-type protein to be retained transiently in the ER and then to be
degraded rapidly after delivery to the plasma membrane. Given the exact
coincidence between the behavior of the mutant and wild-type
polypeptides at two different checkpoints, the most likely explanation
is that they travel together as mixed oligomers. Indeed, the closely
related H+-ATPase of Neurospora crassa has been
suggested to be dimeric based on both kinetic analysis (90) and
radiation inactivation measurements (91), and hexamers have been seen
by cryoelectron microscopy after detergent treatment (17). Future
experiments will look directly for oligomerization of mutant and
wild-type yeast H+-ATPases using the epitope-tagged
constructs. In the meantime, the results of the present study provide a
clear explanation for the fact that G381A behaves genetically as a
co-dominant mutation, slowing but not completely inhibiting growth when
co-expressed with the wild-type PMA1 allele (25); presumably
it does so by reducing the rate at which functional ATPase is delivered
to the cell surface and by accelerating degradation at the plasma membrane.
 |
ACKNOWLEDGEMENTS |
We thank Daniele Urban-Grimal for providing
the WG4a, WG4a-11/22a, W303-1B/D, and W303-1B-pep4 strains, Peter
Novick for supplying strain RH268-1, and Thomas Sommer for strain WO5.
Many thanks also to Philippe Mâle for assistance with confocal
microscopy and photomicrographs and to Natalie DeWitt, Anthony
Ambesi, Juan-Pablo Pardo, Lupe Pardo-Guerra, Valery Petrov, and
Manuel Miranda for advice and support throughout this study. We are
also grateful to Mark Rose for providing antibodies to Kar2p and Randy
Schekman for providing antibodies to Sec7p and Sec12p.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Research Grant GM15761 (to C. W. S.) and by Yale Brown-Coxe
Postdoctoral Fellowship and Philippe Foundation Postdoctoral Fellowship
(to T. F.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Current address: IBMIG, Campus Sciences, Université de
Poitiers, 40 Avenue du Recteur Pineau, 86 022 Poitiers Cedex, France.
§
To whom correspondence and reprint requests should be addressed:
Dept. of Genetics Yale University School of Medicine, 333 Cedar St.,
New Haven, CT 06510. Tel.: 203-785-2690; Fax: 203-785-7227; E-mail:
cw.slaymanlab@yale.edu.
Published, JBC Papers in Press, February 27, 2002, DOI 10.1074/jbc.M112281200
 |
ABBREVIATIONS |
The abbreviations used are:
ER, endoplasmic
reticulum;
WT, wild type;
FITC, fluorescein isothiocyanate;
HA, hemagglutinin;
PBS, phosphate-buffered saline;
VTC, vesicular-tubular
cluster.
 |
REFERENCES |
| 1.
|
Sommer, T.,
and Wolf, D. H.
(1997)
FASEB J.
11,
1227-1233[Abstract]
|
| 2.
|
Brodsky, J. L.,
and McCracken, A. A.
(1999)
Semin. Cell Dev. Biol.
10,
507-513[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Kopito, R. R.
(1999)
Physiol. Rev.
79S,
167-173
|
| 4.
|
Friedlander, R.,
Jarosch, E.,
Urban, J.,
Volkwein, C.,
and Sommer, T.
(2000)
Nat. Cell Biol.
2,
379-384[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Mori, K.
(2000)
Cell
101,
451-454[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Patil, C.,
and Walter, P.
(2001)
Curr. Opin. Cell Biol.
13,
349-356[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Chang, A.,
and Fink, G. R.
(1995)
J. Cell Biol.
128,
39-49[Abstract/Free Full Text]
|
| 8.
|
Hong, E.,
Davidson, A. R.,
and Kaiser, C. A.
(1996)
J. Cell Biol.
135,
623-633[Abstract/Free Full Text]
|
| 9.
|
Luo, W.-J.,
and Chang, A.
(1997)
J. Cell Biol.
138,
731-746[Abstract/Free Full Text]
|
| 10.
|
Luo, W.-J.,
and Chang, A.
(2000)
Mol. Biol. Cell
11,
579-592[Abstract/Free Full Text]
|
| 11.
|
Hicke, L.
(1997)
FASEB J.
11,
1215-1226[Abstract]
|
| 12.
|
Hicke, L.
(1999)
Trends Cell Biol.
9,
107-112[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Wilson, M. H.,
and Limbird, L. E.
(2000)
Biochemistry
39,
693-700[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Lutsenko, S.,
and Kaplan, J. H.
(1995)
Biochemistry
34,
15607-15613[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Serrano, R.,
Kielland-Brandt, M. C.,
and Fink, G. R.
(1986)
Nature
319,
689-693[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Rao, R.,
Nakamoto, R. K.,
Verjovski-Almeida, S.,
and Slayman, C. W.
(1992)
Ann. N. Y. Acad. Sci.
671,
195-203[Medline]
[Order article via Infotrieve]
|
| 17.
|
Auer, M.,
Scarborough, G. A.,
and Kuhlbrandt, W.
(1998)
Nature
392,
840-843[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Toyoshima, C.,
Nakasako, M.,
Nomura, H.,
and Ogawa, H.
(2000)
Nature
405,
647-655[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Walworth, N. C.,
and Novick, P. J.
(1987)
J. Cell Biol.
105,
163-174[Abstract/Free Full Text]
|
| 20.
|
Brada, D.,
and Schekman, R.
(1988)
J. Bacteriol.
170,
2775-2783[Abstract/Free Full Text]
|
| 21.
|
Holcomb, C. L.,
Hansen, W. J.,
Echevarry, T.,
and Schekman, R.
(1988)
J. Cell Biol.
106,
641-648[Abstract/Free Full Text]
|
| 22.
|
Chang, A.,
and Slayman, C. W.
(1991)
J. Cell Biol.
115,
289-295[Abstract/Free Full Text]
|
| 23.
|
Morsomme, P.,
Slayman, C. W.,
and Goffeau, A.
(2000)
Biochim. Biophys. Acta
1469,
133-157[Medline]
[Order article via Infotrieve]
|
| 24.
|
Harris, S. L., Na, S.,
Zhu, X.,
Seto-Young, D.,
Perlin, D. S.,
Teem, J. H.,
and Haber, J. E.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
10531-10535[Abstract/Free Full Text]
|
| 25.
|
DeWitt, N. D.,
dos Santos, C. F.,
Allen, K. E.,
and Slayman, C. W.
(1998)
J. Biol. Chem.
273,
21744-21751[Abstract/Free Full Text]
|
| 26.
|
Moldano, A. M.,
de la Fuente, N.,
and Portillo, F.
(1998)
Genetics
150,
11-19[Abstract/Free Full Text]
|
| 27.
|
Nakamoto, R. K.,
Verjovski-Almeida, S.,
Allen, K. E.,
Ambesi, A.,
Rao, R.,
and Slayman, C. W.
(1998)
J. Biol. Chem.
273,
7338-7344[Abstract/Free Full Text]
|
| 28.
|
Wang, Q.,
and Chang, A.
(1999)
EMBO J.
18,
5972-5982[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Raths, S.,
Rohrer, J.,
Crausaz, F.,
and Riezman, H.
(1993)
J. Cell Biol.
120,
55-65[Abstract/Free Full Text]
|
| 30.
|
Richter-Ruoff, B.,
Wolf, D. H.,
and Hochstrasser, M.
(1994)
FEBS Lett.
354,
50-52[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Thomas, B. J.,
and Rothstein, R.
(1989)
Cell
56,
610-630
|
| 32.
|
Nakamoto, R. K.,
Rao, R.,
and Slayman, C. W.
(1991)
J. Biol. Chem.
266,
7940-7949[Abstract/Free Full Text]
|
| 33.
|
Sikorski, R. S.,
and Hieter, P.
(1989)
Genetics
122,
19-27[Abstract/Free Full Text]
|
| 34.
|
Gietz, R. D.,
and Sugino, A.
(1988)
Gene
74,
527-534[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Sherman, F.,
Hicks, J. B.,
and Fink, G. R.
(1986)
Methods in Yeast Genetics: A Laboratory Manual
, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
|
| 36.
|
Ito, H.,
Fukuda, Y.,
Murata, K.,
and Kimura, A.
(1983)
J. Bacteriol.
153,
163-168[Abstract/Free Full Text]
|
| 37.
|
Goff, C. G.,
Moir, D. T.,
Kohno, T.,
Gravius, T. C.,
Smith, R. A.,
Yamasaki, E.,
and Taunton-Rigby, A.
(1984)
Gene
27,
35-46[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Rose, M. D.,
Winston, F.,
and Heiter, P.
(1990)
Methods in Yeast Genetics
, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
|
| 39.
|
Redding, K.,
Holcomb, C.,
and Fuller, R. S.
(1991)
J. Cell Biol.
113,
527-538[Abstract/Free Full Text]
|
| 40.
|
Franzusoff, A.,
Redding, K.,
Crosby, J.,
Fuller, R. S.,
and Schekman, R.
(1991)
J. Cell Biol.
112,
27-37[Abstract/Free Full Text]
|
| 41.
|
Rose, M. D.,
Misra, L. M.,
and Vogel, J. P.
(1989)
Cell
57,
1211-1221[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Mulholland, J.,
Preuss, D.,
Moon, A.,
Wong, A.,
Drubin, D.,
and Botstein, D.
(1994)
J. Cell Biol.
125,
381-391[Abstract/Free Full Text]
|
| 43.
|
Ambesi, A.,
Allen, K. E.,
and Slayman, C. W.
(1997)
Anal. Biochem.
251,
127-129[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Volland, C.,
Garnier, C.,
and Haguenauer-Tsapis, R.
(1992)
J. Biol. Chem.
267,
23767-23771[Abstract/Free Full Text]
|
| 45.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Abeijon, C.,
Orlean, P.,
Robbins, P. W.,
and Hirschberg, C. B.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
6935-6939[Abstract/Free Full Text]
|
| 47.
|
Feldman, R. I.,
Bernstein, M.,
and Schekman, R.
(1987)
J. Biol. Chem.
262,
9332-9339[Abstract/Free Full Text]
|
| 48.
|
Ambesi, A.,
Pan, R. L.,
and Slayman, C. W.
(1996)
J. Biol. Chem.
271,
22999-23005[Abstract/Free Full Text]
|
| 49.
|
Galan, J. M.,
Moreau, V.,
Andre, B.,
Volland, C.,
and Haguenauer-Tsapis, R.
(1996)
J. Biol. Chem.
271,
10946-10952[Abstract/Free Full Text]
|
| 50.
|
Gong, X.,
and Chang, A.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
9104-9109[Abstract/Free Full Text]
|
| 51.
|
Barlowe, C.,
and Schekman, R.
(1993)
Nature
365,
347-349[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Roberg, K. J.,
Crotwell, M.,
Espenshade, P.,
Gimeno, R.,
and Kaiser, C.
(1999)
J. Cell Biol.
145,
659-672[Abstract/Free Full Text]
|
| 53.
|
Preuss, D.,
Mulholland, J.,
Kaiser, C. A.,
Orlean, P.,
Albright, C.,
Rose, M. D.,
Robbins, P. W.,
and Botstein, D.
(1991)
Yeast
7,
891-911[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Gething, M. J.
(1999)
Semin. Cell Dev. Biol.
10,
465-472[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Chapman, R.,
Sidrauski, C.,
and Walter, P.
(1998)
Annu. Rev. Cell Dev. Biol.
14,
459-485[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Travers, K. J.,
Patil, C. K.,
Wodicka, L.,
Lockhart, D. J.,
Weissman, J. S.,
and Walter, P.
(2000)
Cell
101,
249-258[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Rossi, G.,
Kolstad, K.,
Stone, S.,
Palluault, F.,
and Ferro-Novick, S.
(1995)
Mol. Biol. Cell
6,
1769-1780[Abstract]
|
| 58.
|
Balch, W. E.,
McCaffery, J. M.,
Plutner, H.,
and Farquhar, M. G.
(1994)
Cell
76,
841-852[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Bannykh, S. I.,
and Balch, W. E.
(1997)
J. Cell Biol.
138,
1-4[Free Full Text]
|
| 60.
|
Heinemeyer, W.,
Gruhler, A.,
Mohrle, V.,
Mahe, Y.,
and Wolf, D. H.
(1993)
J. Biol. Chem.
268,
5115-5120[Abstract/Free Full Text]
|
| 61.
|
Potenza, M.,
Bowser, R.,
Muller, H.,
and Novick, P.
(1992)
Yeast
8,
549-558[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Woolford, C. A.,
Daniels, L. B.,
Park, F. J.,
Jones, E. W.,
Van Arsdell, J. N.,
and Innis, M. A.
(1986)
Mol. Cell. Biol.
6,
2500-2510[Abstract/Free Full Text]
|
| 63.
|
Bagnat, M.,
Keranen, S.,
Shevchenko, A.,
Shevchenko, A.,
and Simons, K.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
3254-3259[Abstract/Free Full Text]
|
| 64.
|
Lucero, P.,
Penalver, E.,
Moreno, E.,
and Lagunas, R.
(1997)
Appl. Environ. Microbiol.
63,
3831-3836[Abstract]
|
| 65.
|
Ferreira, T.,
Mason, A. B.,
and Slayman, C. W.
(2001)
J. Biol. Chem.
276,
29613-29616[Free Full Text]
|
| 66.
|
Wright, R.,
Basson, M.,
D'Ari, L.,
and Rine, J.
(1988)
J. Cell Biol.
107,
101-114[Abstract/Free Full Text]
|
| 67.
|
Supply, P.,
Wach, A.,
and Goffeau, A.
(1993)
J. Biol. Chem.
268,
19744-19752[Abstract/Free Full Text]
|
| 68.
|
Elgersma, Y.,
Kwast, L.,
van den Berg, M.,
Snyder, W. B.,
Distel, B.,
bxSubramani, S.,
and Tabak, H. F.
(1997)
EMBO J.
16,
7326-7341[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Biemans, R.,
Thines, D.,
Rutgers, T.,
DeWilde, M.,
and Cabezon, T.
(1991)
DNA Cell Biol.
10,
191-200[Medline]
[Order article via Infotrieve]
|
| 70.
|
Villalba, J. M.,
Palmgren, M. G.,
Berberian, G. E.,
Ferguson, C.,
and Serrano, R.
(1992)
J. Biol. Chem.
267,
12341-12349[Abstract/Free Full Text]
|
| 71.
|
Vergeres, G.,
Yen, T. S. B.,
Aggeler, J.,
Lausier, J.,
and Waskell, L.
(1993)
J. Cell Sci.
106,
249-259[Abstract]
|
| 72.
|
Barco, A.,
and Carrasco, L.
(1995)
EMBO J.
14,
3349-3364[Medline]
[Order article via Infotrieve]
|
| 73.
|
Wanker, E. E.,
Sun, Y.,
Savitz, A. J.,
and Meyer, D. I.
(1995)
J. Cell Biol.
130,
29-39[Abstract/Free Full Text]
|
| 74.
|
De Kerchove d'Exaerde, A.,
Supply, P.,
Dufour, J.-P.,
Bogaerts, P.,
Thinès, D.,
Goffeau, A.,
and Boutry, M.
(1991)
J. Biol. Chem.
270,
23828-23837
|
| 75.
|
De Kerchove d'Exaerde, A.,
Supply, P.,
and Goffeau, A.
(1996)
Yeast
12,
907-916[CrossRef][Medline]
[Order article via Infotrieve]
|
| 76.
|
Kolling, R.,
and Hollenberg, C. P.
(1996)
Eur. J. Biochem.
239,
356-361[Medline]
[Order article via Infotrieve]
|
| 77.
|
Umebayashi, K.,
Hirata, A.,
Fukuda, R.,
Horiuchi, H.,
Ohta, A.,
and Takagi, M.
(1997)
Yeast
13,
1009-1020[CrossRef][Medline]
[Order article via Infotrieve]
|
| 78.
|
Umebayashi, K.,
Hirata, A.,
Horiuchi, H.,
Ohta, A.,
and Takagi, M.
(1999)
Eur. J. Cell Biol.
78,
726-738[Medline]
[Order article via Infotrieve]
|
| 79.
|
Nishikawa, S.,
Hirata, A.,
and Nakano, A.
(1994)
Mol. Biol. Cell
5,
1129-1143[Abstract]
|
| 80.
|
Hauri, H.-P.,
and Schweizer, A.
(1992)
Curr. Opin. Cell Biol.
4,
600-608[CrossRef][Medline]
[Order article via Infotrieve]
|
| 81.
|
Rossanese, O. W.,
Soderholm, J.,
Bevis, B. J.,
Sears, I. B.,
O'Connor, J.,
Williamson, E. K.,
and Glick, B. S.
(1999)
J. Cell Biol.
145,
69-81[Abstract/Free Full Text]
|
| 82.
|
Muñiz, M.,
Morsomme, P.,
and Riezman, H.
(2001)
Cell
104,
313-320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 83.
|
Benito, B.,
Moreno, E.,
and Lagunas, R.
(1991)
Biochim. Biophys. Acta
1063,
265-268[Medline]
[Order article via Infotrieve]
|
| 84.
|
Roth, A. F.,
Sullivan, D. M.,
and Davis, N. G.
(1998)
J. Cell Biol.
142,
949-961[Abstract/Free Full Text]
|
| 85.
|
Kolling, R.,
and Losko, S.
(1997)
EMBO J.
16,
2251-2261[CrossRef][Medline]
[Order article via Infotrieve]
|
| 86.
|
Hammerton, R. W.,
Krzeminski, K. A.,
Mays, R. W.,
Ryan, T. A.,
Wollner, D. A.,
and Nelson, W. J.
(1991)
Science
254,
847-850[Abstract/Free Full Text]
|
| 87.
|
Dubreuil, R. R.,
Wang, P.,
Dahl, S.,
Lee, J.,
and Goldstein, L. S. B.
(2000)
J. Cell Biol.
149,
647-656[Abstract/Free Full Text]
|
| 88.
|
Na, S.,
Hincapie, M.,
McCusker, J. H.,
and Haber, J. E.
(1995)
J. Biol. Chem.
270,
6815-6823[Abstract/Free Full Text]
|
| 89.
|
Wesp, A.,
Hicke, L.,
Palecek, J.,
Lombardi, R.,
Aust, T.,
Munn, A. L.,
and Riezman, H.
(1997)
Mol. Biol. Cell
8,
2291-2306[Abstract/Free Full Text]
|
| 90.
|
Bowman, B. J.
(1983)
J. Biol. Chem.
258,
13002-13007[Abstract/Free Full Text]
|
| 91.
|
Bowman, B. J.,
Berenski, C. J.,
and Jung, C. Y.
(1985)
J. Biol. Chem.
260,
8726-8730[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Nazzari, D. Angoli, S. S. Chow, G. Whitaker, L. Leclair, E. McDonald, V. Macri, K. Zahynacz, V. Walker, and E. A. Accili
Regulation of cell surface expression of functional pacemaker channels by a motif in the B-helix of the cyclic nucleotide-binding domain
Am J Physiol Cell Physiol,
September 1, 2008;
295(3):
C642 - C652.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Pineau, L. Bonifait, J.-M. Berjeaud, P. Alimardani-Theuil, T. Berges, and T. Ferreira
A Lipid-mediated Quality Control Process in the Golgi Apparatus in Yeast
Mol. Biol. Cell,
March 1, 2008;
19(3):
807 - 821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Mason, K. E. Allen, and C. W. Slayman
Effects of C-terminal Truncations on Trafficking of the Yeast Plasma Membrane H+-ATPase
J. Biol. Chem.,
August 18, 2006;
281(33):
23887 - 23898.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Liu and A. Chang
Quality control of a mutant plasma membrane ATPase: ubiquitylation prevents cell-surface stability
J. Cell Sci.,
January 15, 2006;
119(2):
360 - 369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Zaremberg, C. Gajate, L. M. Cacharro, F. Mollinedo, and C. R. McMaster
Cytotoxicity of an Anti-cancer Lysophospholipid through Selective Modification of Lipid Raft Composition
J. Biol. Chem.,
November 11, 2005;
280(45):
38047 - 38058.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Tanaka, K. Ueda, T. Ozawa, I. Kitajima, S. Okamura, M. Morita, S. Yokota, and T. Imanaka
Mutation Study of Antithrombin: The Roles of Disulfide Bonds in Intracellular Accumulation and Formation of Russell Body-Like Structures
J. Biochem.,
March 1, 2005;
137(3):
273 - 285.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. E. de Martin, Y. Du, P. Novick, and S. Ferro-Novick
Ice2p is important for the distribution and structure of the cortical ER network in Saccharomyces cerevisiae
J. Cell Sci.,
January 1, 2005;
118(1):
65 - 77.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Wicky, H. Schwarz, and B. Singer-Kruger
Molecular Interactions of Yeast Neo1p, an Essential Member of the Drs2 Family of Aminophospholipid Translocases, and Its Role in Membrane Trafficking within the Endomembrane System
Mol. Cell. Biol.,
September 1, 2004;
24(17):
7402 - 7418.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Vashist and D. T.W. Ng
Misfolded proteins are sorted by a sequential checkpoint mechanism of ER quality control
J. Cell Biol.,
April 12, 2004;
165(1):
41 - 52.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Coughlan, J. L. Walker, J. C. Cochran, K. D. Wittrup, and J. L. Brodsky
Degradation of Mutated Bovine Pancreatic Trypsin Inhibitor in the Yeast Vacuole Suggests Post-endoplasmic Reticulum Protein Quality Control
J. Biol. Chem.,
April 9, 2004;
279(15):
15289 - 15297.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Huyer, G. L. Longsworth, D. L. Mason, M. P. Mallampalli, J. M. McCaffery, R. L. Wright, and S. Michaelis
A Striking Quality Control Subcompartment in Saccharomyces cerevisiae: The Endoplasmic Reticulum-associated Compartment
Mol. Biol. Cell,
February 1, 2004;
15(2):
908 - 921.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G.-F. Zeng, M. Pypaert, and C. L. Slayman
Epitope Tagging of the Yeast K+ Carrier Trk2p Demonstrates Folding That Is Consistent with a Channel-like Structure
J. Biol. Chem.,
January 23, 2004;
279(4):
3003 - 3013.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. X. Cawley, Y. M. Rodriguez, A. Maldonado, and Y. P. Loh
Trafficking of Mutant Carboxypeptidase E to Secretory Granules in a {beta}-Cell Line Derived from Cpefat/Cpefat Mice
Endocrinology,
January 1, 2003;
144(1):
292 - 298.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Eisenkolb, C. Zenzmaier, E. Leitner, and R. Schneiter
A Specific Structural Requirement for Ergosterol in Long-chain Fatty Acid Synthesis Mutants Important for Maintaining Raft Domains in Yeast
Mol. Biol. Cell,
December 1, 2002;
13(12):
4414 - 4428.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|